The silent protagonist, the dystopian world-building, and the pacing all helped cement Half-Life 2 as one of the most influential shooters ever made. Portal Few games do more with less. Portal was a ...

I'd previously mentioned SourceWorld in my 2024 roundup of Half-Life 2's most impressive mods. Back then, it was closer to a proof-of-concept prototype. A technical feat, but unpolished.

INEC denies registering 2 new political parties INEC boss, Mahmood Yakubu. The Independent National Electoral Commission (INEC) says it has not registered any new political party.

The resignation of Investment, Trade and Industry Minister Tengku Zafrul Abdul Aziz from UMNO to ally PKR has posed questions on the ruling coalition’s future and also whether he’s a dark ...

"I'm not here to apologize but I am here to clarify. This is not a political statement, it is quite literally what it says, so take it at face value," Proulx said via the official Splitgate X account.

The relative power matrix gives organizers a more sophisticated way to think about shifting the balance of power in their ...

On this week’s episode of the Take 2 Podcast, Heidi Hatch is joined by Maura Carabello of the Exoro Group and KNRS host and former House Speaker Greg Hughes to break down a busy week in politics ...

Originally recorded in 2010, Prince’s latest posthumous album is the first full-length record to be released from the late musician’s legendary vault. Kevin E G Perry talks to those who worked ...

Publisher Forever Entertainment and developer MegaPixel Studio announced The House of the Dead 2: Remake will launch for Switch and PC via Steam and GOG on August 7 for $24.99 / €24.99.

Following the latest developments in the Minnesota killings, researchers and political experts confirm there has been an alarming increase in politically motivated acts of violence.

Tencent purchased a 15.75 percent stake in Helldivers 2 developer Arrowhead Game Studios in July 2024 for $83 million, according to Swedish website Dagens Industri (via Insider Gaming).

Investing.com - Aclaris Therapeutics (NASDAQ: ACRS) has launched a placebo-controlled Phase 1a/1b program for its bispecific antibody ATI-052, the company announced Monday. The trial will evaluate ...